1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Novartis India Limited

Novartis India Limited

1,684.50
INR
-83.50
(-4.72%)
Novartis India Limited
NSE:NOVARTIND
(National Stock Exchange of India)

Recent

price

1,684.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
235.04
264.16
282.65
269.78
273.27
215.82
203.45
187.63
182.39
166.6
148.08
156.97
149.49
135.29
144.29
143.5
- -
Revenue per Share
45.89
47.56
37.46
30.83
24.75
62.04
19.1
28.43
20.97
4.08
8.46
-1.51
41.86
34.5
40.87
37.74
- -
Basic EPS, GAAP
27.5
21.97
1.12
-1.88
-20.11
16.93
-14.56
58.12
-84.38
-9.78
-28.07
15.46
18.02
45.93
30.2
18.79
- -
Free Cash Flow per Basic Share
9.98
9.99
9.99
10.02
9.98
9.97
10.66
10.17
10.02
10
10
10
10
47.5
25
25
- -
Dividend per Share
219.95
255.9
281.66
300.79
323.25
373.45
326.8
297.13
307.48
291.9
288.04
280.14
314.15
301.66
317.92
331.23
- -
Book Value per Share
219.92
255.88
281.65
300.79
323.25
373.45
326.8
297.13
307.48
291.9
288.04
280.14
314.15
301.66
317.92
331.23
- -
Tangible Book Value per Share
32
32
32
32
32
32
30
28
25
25
25
25
25
25
25
25
25
Basic Weighted Avg Shares
7,512
8,443
9,034
8,622
8,734
6,898
6,096
5,172
4,503
4,114
3,656
3,876
3,691
3,340
3,563
3,543
- -
Sales/Revenue/Turnover
24.3
17.18
9.87
0.2
1.65
5.06
3.97
-1.24
2.94
0.31
4.11
4.49
18.76
19.54
26.43
26.64
- -
Operating Margin (%)
24
27
36
37
40
35
36
25
32
131
122
97
61
26
22
20
- -
Depreciation Expense
1,467
1,520
1,197
985
791
1,983
572
784
518
101
209
-37
1,034
852
1,009
932
- -
Net Income, GAAP
33
32.34
29.33
- -
13.64
34.91
37.62
50.25
39.64
64.8
47.8
- -
10.42
30.65
22.63
28.14
- -
Effective Tax Rate (%)
19.52
18.01
13.25
11.43
9.06
28.75
9.39
15.15
11.5
2.45
5.72
-0.96
28
25.5
28.32
26.3
- -
Profit Margin (%)
6,277
7,396
8,213
8,489
9,308
10,592
7,883
6,225
6,215
5,803
5,651
4,923
5,178
5,421
6,038
6,233
- -
Working Capital
- -
1
- -
- -
- -
- -
- -
- -
- -
565
498
183
174
51
32
16
- -
LT Debt
7,030
8,179
9,002
9,614
10,331
11,936
9,196
7,336
7,592
7,207
7,112
6,917
7,757
7,448
7,850
8,178
- -
Total Equity
18.86
12.88
7.33
- -
0.37
2.02
1.33
0.78
3.43
0.04
1.27
- -
7.34
6.07
8.86
8.29
- -
Return on Invested Capital (%)
22.65
20.04
13.94
- -
7.93
17.82
5.46
9.81
7.06
1.59
3.19
- -
13.87
11.13
13.17
11.68
- -
Return on Capital (%)
22.63
19.99
13.94
10.59
7.93
17.81
5.42
9.48
6.94
1.36
2.92
-0.53
14.09
11.21
13.19
11.63
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
16
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
16
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
- -
- -
35,416

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
7,683
- -
Cash, Cash Equivalents & STI
- -
6,575
- -
Accounts Receivable, Net
- -
371
- -
Inventories
- -
533
- -
Total Current Liabilities
- -
1,450
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
16
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.11%
3%
4.19%
Free Cash Flow
-83.48%
-11.13%
-37.79%
Net Income, GAAP
-304.44%
-600.62%
-7.65%
Sales/Revenue/Turnover
-6.16%
-0.43%
-0.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
923
871
930
839
3,563
2026
876
- -
859
906
3,543
2027
1,038
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
10.42
8.27
10.31
11.87
40.87
2026
11.19
- -
6.52
10.23
37.74
2027
13.05
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
25
2026
- -
- -
- -
- -
25
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Novartis India Limited is engaged in the pharmaceutical industry, primarily involved in the manufacturing, marketing, and sale of pharmaceutical products and healthcare solutions. Its core offerings include patented medicines, generic pharmaceuticals, biosimilars, ophthalmic products, and vaccines. The company produces a broad range of therapeutic drugs focusing on key areas such as oncology, cardiovascular, immunology, dermatology, and respiratory treatments. Novartis India operates extensively across India and targets healthcare providers, hospitals, pharmacies, and patients within the region. Founded in 1994 and headquartered in Mumbai, India, Novartis India Limited is a subsidiary of the global healthcare company Novartis AG. The company focuses on research and development, manufacturing, and distribution of medicines and vaccines, serving both domestic and international markets. Recent developments in the last 1-2 years include new product launches in oncology and biosimilars, strategic collaborations enhancing its vaccine portfolio, and expansion of its presence in specialty medicines. These initiatives reflect Novartis India’s commitment to innovation and strengthening its market leadership in complex and specialty therapies within the Indian pharmaceutical landscape. The company operates in pharmaceutical manufacturing and marketing segments and caters to a diverse customer base including hospitals, clinics, and retail pharmacies across India. Novartis India has also made operational enhancements aimed at improving access to advanced healthcare treatments. Its portfolio includes drug categories such as branded generics, patented drugs under international licenses, biosimilar monoclonal antibodies, and ophthalmic solutions, ensuring wide coverage of therapeutic areas. These comprehensive offerings position Novartis India as a significant player in the Indian pharmaceutical industry, delivering high-quality healthcare products and solutions.